CXCR
Chemokine receptors are classified into four subgroups, the CC chemokine receptors (CCRs), CXCRs, XCRs and CX3-CRs. In humans, 18 chemokine receptors, comprising 10 CCRs, 6CXCRs, 1 XCR, and 1 CX3CR, have been characterised and act as receptors for at least 44 chemokine ligands. The CXC receptor 1 and 2 (CXCR1 and CXCR2) have been well characterised in vertebrates. In mammals and birds, the two receptors are shared by the ELR+ CXC ligands, namely the CXCL8 family members that have proinflammatory roles in recruitment of neutrophils, monocytes and macrophages to sites of infection. Activation of CXCR1 and CXCR2 leads to a cascade of cellular events responsible for migration, homeostasis and adhesion of the target cells. CXCR1 primarily binds with CXCL6–8 whilst CXCR2 is less ligand specific, interacting with almost all of the ELR+ CXC chemokines including CXCL1–3 and CXCL5–8. CXCR1 and CXCR2 recruit GRK2 and GRK6 respectively, to regulate leucocyte functions. This can lead to functional differences. CXCR2 but not CXCR1 is involved in CXCL8 mediated angiogenesis and cancer growth. CXCR3 is the sole receptor shared by three closely related ELR- chemokines CXCL9–11 and also interacts with CXCL4 and CCL21. CXCR4 has been discovered as a single copy gene in agnathan and gnathostome vertebrates except for teleosts where duplicated CXCR4 (CXCR4a and4b), and their ligands CXCL12 (CXCL12a and 12b), are present.
References
1.Zou J,et al. Gen Comp Endocrinol. 2015 May 1;215:117-31.
References
1.Zou J,et al. Gen Comp Endocrinol. 2015 May 1;215:117-31.
Autophagy
CXCR
-
FC131 TFA
catalog no : M37915
cas no: 842166-42-1
FC131 TFA (606968-52-9 free base) (FC131 TFA) is an antagonist of CXCR4 that inhibits the binding of [125I] -sdf-1 to CXCR4(IC50 : 4.5 nM ), and has anti-hiv activity. -
CXCL-CXCR1/2-IN-1
catalog no : M37526
cas no: 2415653-55-1
CXCL-CXCR1/2-IN-1 is an orally active and potent inhibitor of the ELR+CXCL-CXCR1/2 pathway with anticancer and anti-angiogenic activity and can be used to study cardiovascular disease and cancer. -
Ulocuplumab
catalog no : M36724
cas no: 1375830-34-4
Ulocuplumab (BMS-936564) is a fully human anti-CXCR4 IgG4 antibody.Ulocplumab exhibits antitumor activity in acute myeloid leukemia (AML), non-Hodgkin's lymphoma (NHL), and multiple myeloma transplantation models. -
Mogamulizumab
catalog no : M36717
cas no: 1159266-37-1
Mogamulizumab (KW-0761) is a monoclonal antibody targeting T cell CC chemokine receptor 4. -
Eldelumab
catalog no : M36693
cas no: 946414-98-8
Eldelumab (BMS-936557) is a humanized anti-IP-10 IgG type 1 monoclonal antibody with inhibitory activity against CXCL10. It has anti-inflammatory properties, selectively binds to CXCL10, and can be used in the study of rheumatoid arthritis, ulcerative colitis, and Crohn's disease.